EUVIMEDEUVIMED entdecken
Multizentrische Studie

Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer

Romain-David Seban iD, Laurence Champion, Alexandre De Moura, Florence Lerebours, Delphine Loirat, Jean-Yves Pierga, Lounes Djerroudi, Thomas Genevee, Virginie Huchet, Nina Jehanno, Francois-Clement Bidard, Irene Buvat

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-06929-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Romain-David Seban und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210, Saint-Cloud, France. romain.seban@gmail.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Immunoconjugates, Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to evaluate the association between pretreatment [18F]FDG PET/CT-derived biomarkers and outcomes in metastatic breast cancer (mBC) patients treated with antibody-drug conjugates (ADCs) Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd). METHODS: A retrospective bicentric analysis was conducted on triple-negative mBC (mTNBC) patients treated with SG and HER2-low mBC patients treated with T-DXd, who underwent [18F]FDG PET/CT scans before therapy. Key biomarkers, including maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV) and maximum tumor dissemination (Dmax), were measured. Their prognostic value for progression-free survival (PFS) and overall survival (OS) was assessed using Cox models and Kaplan-Meier curves. RESULTS: 128 patients were included: 71 mTNBC treated with SG and 57 HR-positive and -negative HER2-low mBC treated with T-DXd. Median follow-up was 12.9 months. In the SG cohort, median PFS and OS were 4.8 and 8.9 months, respectively. High Dmax (HR 2.1, 95% CI 1.1-4.3) and high TMTV (HR 2.9, 95% CI 1.2-6.6) were independently associated with shorter OS. In the T-DXd cohort, median PFS and OS were 5.8 and 9.0 months, respectively. High Dmax (HR 2.1, 95% CI 1.2-3.9) and high TMTV (HR 2.4, 95% CI 1.0-6.5) independently correlated with shorter PFS and shorter OS, respectively. CONCLUSION: Pretreatment [18F]FDG PET/CT-derived biomarkers, namely TMTV and Dmax, have significant prognostic value in patients with mTNBC and HER2-low mBC treated with SG and T-DXd. These biomarkers improve prognostic prediction and may optimize treatment strategies, warranting their clinical use, but larger studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18ImmunoconjugatesBreast NeoplasmsBiomarkers, TumorHumansFemaleMiddle AgedRetrospective StudiesAgedAdultNeoplasm MetastasisTrastuzumabAntibodies, Monoclonal, HumanizedTreatment OutcomeCamptothecinPrognosisAged, 80 and over

Stichwörter der Autor:innen

Antibody–drug conjugatesMetabolic tumor burdenMetastatic breast cancerSurvival outcomesTumor dissemination[18F]FDG PET/CT

Substanzen

Fluorodeoxyglucose F18ImmunoconjugatesBiomarkers, TumorTrastuzumabAntibodies, Monoclonal, Humanizedsacituzumab govitecantrastuzumab deruxtecanCamptothecin

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210, Saint-Cloud, France. romain.seban@gmail.com.
  • Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL University, Institut Curie, Paris Saclay University, 91400, Orsay, France. romain.seban@gmail.com.
  • Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210, Saint-Cloud, France.
  • Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL University, Institut Curie, Paris Saclay University, 91400, Orsay, France.
  • Department of Medical Oncology, Institut Curie, 92210, Saint-Cloud, France.
  • Department of Medical Oncology, Institut Curie, 75005, Paris, France.

ORCID-Profile: Romain-David Seban

Zitieren

APA

Seban, R. D., Champion, L., De Moura, A., Lerebours, F., Loirat, D., Pierga, J. Y., Djerroudi, L., Genevee, T., Huchet, V., Jehanno, N., Bidard, F. C., & Buvat, I. (2025). Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06929-x

Vancouver

Seban RD, Champion L, De Moura A, Lerebours F, Loirat D, Pierga JY, et al. Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06929-x

BibTeX
@article{Seban2025,
  author = {Seban, Romain-David and Champion, Laurence and De Moura, Alexandre and Lerebours, Florence and Loirat, Delphine and Pierga, Jean-Yves and Djerroudi, Lounes and Genevee, Thomas and Huchet, Virginie and Jehanno, Nina and Bidard, Francois-Clement and Buvat, Irene},
  title = {Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-06929-x}
}
Kostenlos starten →